<DOC>
	<DOCNO>NCT00546780</DOCNO>
	<brief_summary>This phase 3 , open label trial patient multiple myeloma first relapse . Trial compare tanespimycin ( KOS-953 ) , combination fix dose bortezomib versus bortezomib alone .</brief_summary>
	<brief_title>A Study Tanespimycin ( KOS-953 ) Patients With Multiple Myeloma First Relapse</brief_title>
	<detailed_description>Phase 3 combination study compare tanespimycin ( KOS-953 ) plus bortezomib bortezomib alone patient multiple myeloma first relapse failure previous anti-cancer therapy and/or bone marrow transplantation . Primary objective compare progression-free survival ( PFS ) associate use tanespimycin ( KOS-953 ) combination bortezomib versus associate administration bortezomib alone .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Good Performance Status Documented evidence multiple myeloma Documented progression disease initial response one line therapy Measurable disease ( serum Mprotein &gt; .5g/dl &gt; 200 mg urinary M protein excretion ) Prior treatment heat shock 90 inhibitor investigational proteasome inhibitor Known active infection HAV , HBV , HCV , HIV Administration chemotherapy , radiation therapy , immune therapy within 21 day prior randomization . Acute diffuse infiltrate pulmonary disease pericardial dise</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Heat Shock Protein 90</keyword>
	<keyword>Hsp90</keyword>
	<keyword>KOS-953</keyword>
	<keyword>17-AAG</keyword>
	<keyword>bortezomib</keyword>
	<keyword>first relapse</keyword>
	<keyword>tanespimycin</keyword>
	<keyword>TIME-1</keyword>
</DOC>